Angel Rosario, MD
Gastroenterology · Tampa, FLNPI 1023127909
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 1,034 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,034 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Ipsen Bioscience Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Johnson & Johnson$1K
- Vivus LLC$999
- plus $8K from 43 others
Across 397 payments — averaging $3593.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$306K
- Boehringer Ingelheim International GmbH$291K
- Madrigal Pharmaceuticals$270K
- Intercept Pharmaceuticals, Inc.$248K
- Bristol Myers Squibb$162K
- Ipsen Bioscience Inc.$55K
- plus $95K from 4 others
What the payments were for
- Consulting fees$100%
- Travel & lodging$1,3276%
- Food & beverage$19,69293%
- Education$1521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$281
- Reltone 400 Mg$281
- OCALIVA$125
- Skyrizi$121
- STELARA$118
How this compares
$21,180 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 199 | $730,765 |
| ZenpepLipase/Protease/Amylase | 75 | $260,108 |
| LinzessLinaclotide | 193 | $182,799 |
| Humira PenAdalimumab | 24 | $163,204 |
| SucraidSacrosidase | 11 | $152,134 |
| XifaxanRifaximin | 25 | $68,718 |
| Dexlansoprazole DrDexlansoprazole | 79 | $29,962 |
| MotegrityPrucalopride Succinate | 34 | $20,789 |
| TrulancePlecanatide | 33 | $17,784 |
| MovantikNaloxegol Oxalate | 14 | $12,683 |
| DexilantDexlansoprazole | 12 | $10,863 |
| Famotidine | 318 | $9,834 |
| VoqueznaVonoprazan Fumarate | 14 | $8,475 |
| Sucralfate | 69 | $8,375 |
| Mesalamine | 40 | $8,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $4,720 | $913,564392 claims |
| Aimmune Therapeutics, Inc.Zenpep | $246 | $260,10875 claims |
| QOL Medical, LLCSucraid | $637 | $152,13411 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $2,198 | $86,50258 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $1,791 | $31,65246 claims |
| Redhill Biopharma Inc.Movantik | $575 | $12,68314 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $79 | $8,47514 claims |
| SandozLansoprazole | $14 | $97137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Tampa
- Adnan MuhammadTampa$150K
- John JacobsTampa$141K
- Renee Marchioni BeeryTampa$126K
- Michael DanielTampa$52K
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.